An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy

NCT01103960 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

324

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: Telmisartan80mg+Amlodipine5mg
DRUG: amlodipine 5mg
DRUG: Telmisartan80mg+Amlodipine 5mg

Sponsor

Boehringer Ingelheim